0001127602-22-014148.txt : 20220511 0001127602-22-014148.hdr.sgml : 20220511 20220511162650 ACCESSION NUMBER: 0001127602-22-014148 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220509 FILED AS OF DATE: 20220511 DATE AS OF CHANGE: 20220511 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meline David W CENTRAL INDEX KEY: 0001444612 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 22914144 MAIL ADDRESS: STREET 1: 3M COMPANY STREET 2: 3M OFFICE OF GENERAL COUNSEL CITY: ST PAUL STATE: MN ZIP: 55144-1000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-05-09 0001682852 Moderna, Inc. MRNA 0001444612 Meline David W C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Financial Officer Common Stock 2022-05-09 4 M 0 348 134.40 A 2739 D Common Stock 2022-05-10 4 S 0 156 133.7138 D 2583 D Restricted Stock Units 0 2022-05-09 4 M 0 348 0 D Common Stock 348 3830 D Restricted stock units convert into common stock on a one-for-one basis. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. /s/ Brian Sandstrom, as Attorney-in-Fact 2022-05-11